Antihypertensive Drugs Market to Reach USD 33.86 Billion by 2032

According to analysts at Vantage Market Research, the Global Antihypertensive Drugs Market size is worth USD 25.5 Billion in 2023 and is projected to reach USD 33.86 Billion by 2032, growing at a CAGR (Compound Annual Growth Rate) of 3.2% from 2024 to 2032. The antihypertensive drugs market is driven by the rising prevalence of hypertension and related cardiovascular conditions, alongside the growing awareness and improved diagnosis. Opportunities include the advancements in drug formulations and personalized medicine, as well as expanding access to healthcare in the emerging markets.

Market Overview

Antihypertensive medications are utilized to manage high blood pressure, with various types designed to address the condition in different ways. Some drugs remove excess fluid and salt from the body, others relax and widen blood vessels, and some slow the heart rate. Responses to these medications can differ among individuals, with some experiencing better results and fewer side effects with specific drugs. Often, a combination of antihypertensive agents is necessary to effectively control blood pressure. The growth of the antihypertensive drugs market is driven by initiatives from both private and government organizations, as well as increasing awareness about hypertension. For example, Hanmi Pharmaceutical announced the introduction of its hypertension drug Amosartan in China under the brand name Meiyaping, marking the launch of the first domestically developed blood pressure combination therapy in the Chinese market.

According to the World Health Organization (WHO) in May 2023, approximately 1.28 billion people globally suffer from hypertension, with two-thirds residing in low- and middle-income countries. The rise in hypertension cases is attributed to sedentary lifestyles, unhealthy diets, and an aging population. Major causes include kidney diseases, diabetes, obstructive sleep apnea, and other cardiovascular conditions, which have significantly increased hypertension prevalence over the years.

Lupin Receives FDA Approval for Generic Topiramate Extended-Release Capsules to be Manufactured in India

In July 2024, Lupin Limited, a global pharmaceutical leader, announced that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Topiramate Extended-Release Capsules in 25 mg, 50 mg, 100 mg, and 200 mg. This approval allows Lupin to offer a generic version of Supernus Pharmaceuticals Trokendi XR Extended-Release Capsules in the same dosages. The product will be produced at Lupin’s facility in Pithampur, India. Topiramate Extended-Release Capsules are indicated for use as initial monotherapy in treating partial-onset or primary generalized tonic-clonic seizures.

Key Takeaways from the Report

• North America dominated the market with a 42.2% share in 2023, driven by its advanced healthcare infrastructure, high prevalence of hypertension, substantial investments in healthcare R&D, and the strong presence of major companies
• Asia Pacific is anticipated to experience significant growth with a notable compound annual growth rate (CAGR) throughout the forecast period
• In 2023, Primary Hypertension segment dominated the global market due to its widespread prevalence, increased awareness and diagnosis rates, and the availability of effective treatments
• Based on End User, the Hospital Pharmacy segment held the largest market share in 2023, driven by the high volume of prescriptions filled in hospitals, the broad range of antihypertensive medications available, and the reliance on hospital pharmacies for managing acute and severe hypertension cases

Top Companies

• Novartis AG
• AstraZeneca plc
• Lupin
• Daiichi Sankyo Company
• Limited
• Johnson & Johnson
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• SANOFI
• Boehringer Ingelheim International GmbH
• Merck & Co. Inc

Latest News

FDA Approves Aprocitentan (Tryvio) for Treatment-Resistant Hypertension

• In March 2024, The US Food and Drug Administration (FDA) has authorized aprocitentan (Tryvio) for use alongside other antihypertensive medications to manage blood pressure in adults with treatment-resistant hypertension. Aprocitentan is the first endothelin receptor antagonist approved for hypertension.